Antithrombotic therapy with warfarin or aspirin unequivocally reduces the risk of stroke in patients with chronic atrial fibrillation, with warfarin being more effective but carrying higher bleeding risk.
Does antithrombotic therapy (warfarin or aspirin) prevent stroke in patients with chronic atrial fibrillation?
This position statement supports the routine use of warfarin or aspirin for stroke prevention in patients with chronic atrial fibrillation.
The American Society of Health-System Pharmacists (ASHP) supports the routine use of antithrombotic therapy (warfarin or aspirin) for stroke prevention in patients with chronic atrial fibrillation (AF). Antithrombotic therapy given to patients with AF for primary prevention (before the first stroke or episode of systemic embolism) or as a secondary intervention (after stroke or systemic embolism has occurred) unequivocally reduces the risk of stroke.1 Warfarin is more effective than aspirin but carries a higher risk of bleeding and requires regular medical and therapeutic monitoring. ASHP supports recommendations established by the American College of Chest Physicians (ACCP) (Table 11) for the use of antithrombotic therapy in patients with AF to reduce the morbidity and mortality associated with stroke.1 ASHP encourages the use of warfarin, if it can be administered safely, in all patients with chronic AF who are younger than 75 years and have one or more...
Edith A. Nutescu (Wed,) conducted a review in Chronic Atrial Fibrillation. Antithrombotic therapy (warfarin or aspirin) was evaluated on Stroke prevention. Antithrombotic therapy with warfarin or aspirin unequivocally reduces the risk of stroke in patients with chronic atrial fibrillation, with warfarin being more effective but carrying higher bleeding risk.